• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
WU Zhenhui,WU Min,GAO Yao,LIANG Zhenyao,WU Xinping,ZHOU Lu,YUAN Qiuping,LIU Fan,ZENG Yingjian.Research progress of curcumin and its derivatives in treatment of acute myeloid leukemia[J].Journal Of Pharmaceutical Research,2026,45(5):542-551[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1782times   Download 796次 QR Code for this article
Scan with your phone!
姜黄素及其衍生物在急性髓系白血病治疗中的研究进展
伍振辉,吴敏,高姚,梁祯尧,吴欣平,周露,袁秋平,刘凡,曾英坚
Font:Larger+|Default|Smaller-
(江西中医药大学附属医院血液科,江西 南昌 330006)
摘要:
急性髓系白血病(AML)是一种高度侵袭性的恶性血液肿瘤疾病,因其复杂的病理机制和高复发率,给临床治疗带来了巨大挑战。姜黄素,作为一种来源于天然植物姜黄的多酚类化合物,因其多靶点、多机制的抗癌特性,近年来在AML治疗领域引起广泛关注。本文系统综述了姜黄素及其衍生物在AML中的研究进展,重点阐述了其通过诱导凋亡、诱导焦亡、调节自噬、逆转多药耐药、抑制免疫逃逸、表观遗传调控、诱导铁死亡的作用机制。同时,探讨了姜黄素与传统化疗药物的协同增效作用及其衍生物在提升疗效的应用,并针对当前研究的局限性分析了实现临床转化所面临的挑战,强调了药物联合增敏减毒和开展大规模临床试验的必要性。本综述旨在为姜黄素相关抗AML治疗策略的深入研究和临床应用提供理论依据和参考。
关键词:  急性髓系白血病  姜黄素  姜黄素及其衍生物  姜黄素联合  药理作用
DOI:10.13506/j.cnki.jpr.2026.05.010
基金项目:国家自然科学基金项目(No.82305159、82260914)
Received Date:November 11, 2025   Revision Date:December 04, 2025   Publication Date:May 29, 2026
Research progress of curcumin and its derivatives in treatment of acute myeloid leukemia
WU Zhenhui,WU Min,GAO Yao,LIANG Zhenyao,WU Xinping,ZHOU Lu,YUAN Qiuping,LIU Fan,ZENG Yingjian
(Department of Hematology, Jiangxi University of Chinese Medicine Affiliated Hospital, Nanchang 330000,China)
Abstract:
Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy. Its complex pathological mechanisms and high recurrence rate pose significant challenges to clinical treatment. Curcumin, a polyphenolic compound derived from the natural plant Curcuma longa, has attracted widespread attention in AML treatment in recent years due to its multi-targeted and multi-mechanistic anticancer properties. This article systematically reviews the research progress of curcumin and its derivatives in AML, focusing on elaborating their mechanisms of action, including inducing apoptosis, triggering pyroptosis, regulating autophagy, reversing multidrug resistance, inhibiting immune escape, mediating epigenetic regulation, and inducing ferroptosis. Meanwhile, it discusses the synergistic efficacy-enhancing effects of curcumin with traditional chemotherapeutic drugs and the application of its derivatives in improving therapeutic efficacy. Additionally, it analyzes the challenges for clinical translation based on the limitations of current research, emphasizing the necessity of drug combination for sensitization and toxicity reduction, as well as the conduction of large-scale clinical trials. This review aims to provide a theoretical basis and reference for in-depth research and clinical application of curcumin-related anti-AML therapeutic strategies.
Key words:  Acute myeloid leukemia  Curcumin  Curcumin and its derivatives  Curcumin combination  Pharmacological activities
Today's Visits:455    Total Visits:2383144
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.